Overview
Compare with LENSAR, Inc., CARLSMED, INC. or CVRx (United States), or pick any stock.
- TickerAPYX on Nasdaq2
- IndustrySurgical & Medical Instruments & Apparatus2
- HeadquartersClearwater, United States2
- Incorporated inDE3
- Business address5115 Ulmerton Road, Clearwater, Fl 337603
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation2
- LEI5299009QZVYUYO082S452
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressc/o UNITED CORPORATE SERVICES, INC., 874 WALKER RD STE C, 19904 Dover, United States2
- Registered withDivision of Corporations, Department of State, 9492152
See how the biggest companies compare on our leaderboards
We have included or incorporated by reference into this report, and from time to time may make in our public filings, press releases or other public statements, certain statements that may constitute forward-looking statements. These include without limitation those under “Business” in Part I, Item 1, “Risk Factors” in Part I, Item 1A, “Legal Proceedings” in Part I, Item 3 and “Management's Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7. In addition, our management my make forward-looking statements to analysts, investors, representatives of the media and others. These forward-looking statements are not historical facts and represent only our beliefs regarding future events, many of which, by their nature, are inherently uncertain and beyond our control. We may, in some cases, use words such as “project”, “believe”, “anticipate”, “plan”, “exp…5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
62.5%Gross margin6
-12.2%Operating margin6
-21.2%Net margin6
9.9%Revenue growth, 20256
-77.1%Return on equity6
2.40×Debt to equity6
-$9.1MFree cash flow6
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
Surgical Aesthetics brought in 86% of the revenue Apyx Medical Corp broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2024 | 2025 |
|---|---|---|
| Surgical Aesthetics | $38.6M | $45.3M |
| OEM | $9.5M | $7.5M |
Regions
United States brought in 73% of the revenue Apyx Medical Corp broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| United States | $34.0M | $38.8M |
| Outside the United States | $14.1M | $14.0M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue37¢$19.8M
- Research and development6¢$3.4M
- Selling, general and admin30¢$15.8M
- Other costs26¢$13.6M
- Income tax1¢$270.0K
Out of $52.8M in revenue.6 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Sales, net | $52.8M | $48.1M | |
| Cost of sales | $19.8M | $18.7M | |
| Gross profit | $33.0M | $29.4M | |
| Research and development | $3.4M | $5.1M | |
| Professional services | $6.3M | $6.9M | |
| Salaries and related costs | $14.0M | $17.4M | |
| Selling, general and administrative | $15.8M | $18.9M | |
| Total other costs and expenses | $39.5M | $48.2M | $53.7M |
| Loss from operations | -$6.4M | -$18.8M | |
| Interest income | $1.1M | $1.6M | |
| Interest expense | -$5.6M | -$5.9M | |
| Other Operating Income (Expense), Net | $92.0K | -$161.0K | |
| Total other expense, net | -$4.4M | -$4.5M | |
| Loss before income taxes | -$10.8M | -$23.3M | |
| Income tax expense | $270.0K | $252.0K | |
| Net loss | -$11.1M | -$23.6M | |
| Net loss attributable to non-controlling interest | $106.0K | -$96.0K | |
| Net loss attributable to stockholders | -$11.2M | -$23.5M | |
| Basic and diluted (in dollars per share) | -$0.27 | -$0.66 | |
| Weighted average number of shares outstanding - basic and diluted (in shares) | 41.1M shares | 35.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2024-10-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $31.7M | $31.7M | ||
| Trade accounts receivable, net of allowance of $1,020 and $1,000 | $16.8M | $15.5M | ||
| Inventories, net of provision for obsolescence of $1,207 and $1,032 | $8.6M | $7.6M | ||
| Prepaid expenses and other current assets | $1.4M | $1.7M | ||
| Total current assets | $58.5M | $56.4M | ||
| Property and equipment, net | $2.4M | $2.0M | ||
| Operating lease right-of-use assets | $4.2M | $4.7M | ||
| Finance lease right-of-use assets | $28.0K | $48.0K | ||
| Other assets | $1.8M | $1.7M | ||
| Total assets | $66.8M | $64.8M | ||
| Accounts payable | $3.1M | $2.6M | ||
| Accrued expenses and other current liabilities | $8.2M | $7.8M | ||
| Current portion of operating lease liabilities | $407.0K | $335.0K | ||
| Current portion of finance lease liabilities | $21.0K | $20.0K | ||
| Total current liabilities | $11.7M | $10.7M | ||
| Long-term debt, net of debt discounts and issuance costs | $34.8M | $33.9M | ||
| Long-term operating lease liabilities | $4.1M | $4.5M | ||
| Long-term finance lease liabilities | $12.0K | $33.0K | ||
| Long-term contract liabilities | $1.1M | $1.1M | ||
| Other liabilities | $347.0K | $259.0K | ||
| Total liabilities | $52.0M | $50.5M | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, $0.001 par value; 75,000,000 shares authorized; 41,785,946 issued and outstanding as of December 31, 2025, and 37,793,886 issued and outstanding as of December 31, 2024 | $42.0K | $38.0K | ||
| Additional paid-in capital | $103.6M | $92.1M | ||
| Accumulated deficit | -$89.1M | -$77.9M | ||
| Total stockholders equity | $14.5M | $14.2M | ||
| Non-controlling interest | $291.0K | $125.0K | ||
| Total equity | $14.8M | $14.3M | $26.9M | |
| Total liabilities and equity | $66.8M | $64.8M | ||
| Allowance for credit loss | $1.0M | $1.0M | ||
| Provision for obsolescence | $1.2M | $1.0M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | $0.00 | |
| Common stock, authorized (in shares) | 75.0M shares | 75.0M shares | ||
| Common stock, issued (in shares) | 41.8M shares | 37.8M shares | ||
| Common stock, outstanding (in shares) | 41.8M shares | 37.8M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-10-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $31.7M | $31.7M | ||
| Trade accounts receivable, net of allowance of $1,020 and $1,000 | $16.8M | $15.5M | ||
| Inventories, net of provision for obsolescence of $1,207 and $1,032 | $8.6M | $7.6M | ||
| Prepaid expenses and other current assets | $1.4M | $1.7M | ||
| Total current assets | $58.5M | $56.4M | ||
| Property and equipment, net | $2.4M | $2.0M | ||
| Operating lease right-of-use assets | $4.2M | $4.7M | ||
| Finance lease right-of-use assets | $28.0K | $48.0K | ||
| Other assets | $1.8M | $1.7M | ||
| Total assets | $66.8M | $64.8M | ||
| Accounts payable | $3.1M | $2.6M | ||
| Accrued expenses and other current liabilities | $8.2M | $7.8M | ||
| Current portion of operating lease liabilities | $407.0K | $335.0K | ||
| Current portion of finance lease liabilities | $21.0K | $20.0K | ||
| Total current liabilities | $11.7M | $10.7M | ||
| Long-term debt, net of debt discounts and issuance costs | $34.8M | $33.9M | ||
| Long-term operating lease liabilities | $4.1M | $4.5M | ||
| Long-term finance lease liabilities | $12.0K | $33.0K | ||
| Long-term contract liabilities | $1.1M | $1.1M | ||
| Other liabilities | $347.0K | $259.0K | ||
| Total liabilities | $52.0M | $50.5M | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, $0.001 par value; 75,000,000 shares authorized; 41,785,946 issued and outstanding as of December 31, 2025, and 37,793,886 issued and outstanding as of December 31, 2024 | $42.0K | $38.0K | ||
| Additional paid-in capital | $103.6M | $92.1M | ||
| Accumulated deficit | -$89.1M | -$77.9M | ||
| Total stockholders equity | $14.5M | $14.2M | ||
| Non-controlling interest | $291.0K | $125.0K | ||
| Total equity | $14.8M | $14.3M | $26.9M | |
| Total liabilities and equity | $66.8M | $64.8M | ||
| Allowance for credit loss | $1.0M | $1.0M | ||
| Provision for obsolescence | $1.2M | $1.0M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | $0.00 | |
| Common stock, authorized (in shares) | 75.0M shares | 75.0M shares | ||
| Common stock, issued (in shares) | 41.8M shares | 37.8M shares | ||
| Common stock, outstanding (in shares) | 41.8M shares | 37.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$11.1M | -$23.6M |
| Depreciation and amortization | $655.0K | $599.0K |
| Provision for inventory obsolescence | $341.0K | $163.0K |
| Provision for product warranties | $214.0K | $304.0K |
| Loss on disposal of property and equipment | $19.0K | $13.0K |
| Stock based compensation | $2.0M | $4.0M |
| Allowance for credit losses | $423.0K | $396.0K |
| Non-cash lease expense | $86.0K | $112.0K |
| Non-cash interest expense | $956.0K | $1.2M |
| Trade receivables | -$1.3M | -$2.0M |
| Prepaid expenses and other assets | $237.0K | $857.0K |
| Inventories | -$1.1M | $2.3M |
| Accounts payable | $355.0K | -$63.0K |
| Accrued and other liabilities | $209.0K | -$2.3M |
| Net cash used in operating activities | -$8.0M | -$18.0M |
| Purchases of property and equipment | -$1.1M | -$722.0K |
| Net cash used in investing activities | -$1.1M | -$722.0K |
| Proceeds from stock option exercises | $488.0K | $0 |
| Proceeds from capital raise | $9.3M | $7.0M |
| Payment of direct incremental costs in capital raise | -$248.0K | -$224.0K |
| Payment of debt costs | $0 | -$11.0K |
| Repayment of finance lease liabilities | -$20.0K | -$20.0K |
| Contributions from non-controlling interest | $60.0K | $0 |
| Net cash provided by financing activities | $9.6M | $6.7M |
| Net change in cash and cash equivalents | -$1.0K | -$11.9M |
| Effect of exchange rates on cash | -$466.0K | $113.0K |
| Interest | $4.6M | $4.7M |
| Income taxes | $258.0K | $382.0K |
| Fair value of common stock issued in debt amendment | $0 | $183.0K |
| Transfer of machinery and equipment to inventory | $78.0K | $62.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Apyx Medical Corp sits at the top of its group. 4 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Apyx Medical Corp
- ROYCE & ASSOCIATES LP Filed SCHEDULE 13G/A on Apyx Medical Corp, latest Jul 21, 2026 (5 filings since Jan 23, 2024)
- Nantahala Capital Management, LLC Filed SCHEDULE 13G/A on Apyx Medical Corp, latest Feb 13, 2026 (2 filings since Feb 14, 2025)
- Archon Capital Management LLC Filed SC 13G on Apyx Medical Corp, latest Oct 31, 2024 (6 filings since Feb 14, 2022)
- Stavros G. Vizirgianakis Filed SC 13D/A on Apyx Medical Corp, latest May 9, 2024 (2 filings since Apr 1, 2024)
- Orin Hirschman Filed SC 13G/A on Apyx Medical Corp, latest Mar 25, 2024 (5 filings since May 12, 2023)
- Divisadero Street Capital Management, LP Filed SC 13G/A on Apyx Medical Corp, latest Feb 14, 2024 (2 filings since May 19, 2023)
- PURA VIDA INVESTMENTS, LLC Filed SC 13G/A on Apyx Medical Corp, latest Feb 14, 2024 (3 filings since Nov 23, 2022)
- RTW INVESTMENTS, LP Filed SC 13G/A on Apyx Medical Corp, latest Feb 14, 2024 (2 filings since Feb 14, 2022)
- Cowen Financial Products LLC Filed SC 13G/A on Apyx Medical Corp, latest Feb 2, 2024 (3 filings since Jan 20, 2022)
- BlackRock Filed SC 13G on Apyx Medical Corp, latest Jul 8, 2022 (2 filings since Feb 1, 2022)
- Apyx Medical Corp Clearwater, Florida, United States
- Apyx Bulgaria EOOD Subsidiary · Bulgaria
- Apyx China Holding Corp. Subsidiary · Delaware, United States
- Apyx SY Medical Devices (NINGBO) Co., LTD. Subsidiary · China
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Apyx Medical Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Construction in progress | $162.0K6 Dec 31, 2025 | $635.0K6 Dec 31, 2024 | −74.5% |
| Property and equipment, before depreciation | $6.5M6 Dec 31, 2025 | $5.3M6 Dec 31, 2024 | +21.7% |
| Accumulated depreciation | $4.3M6 Dec 31, 2025 | $4.0M6 Dec 31, 2024 | +7.6% |
| Property and equipment, net | $2.4M6 Dec 31, 2025 | $2.0M6 Dec 31, 2024 | +19.3% |
| Finance-lease assets | $28.0K6 Dec 31, 2025 | $48.0K6 Dec 31, 2024 | −41.7% |
| Operating-lease assets (leased space) | $4.2M6 Dec 31, 2025 | $4.7M6 Dec 31, 2024 | −10.3% |
Investments
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $8.6M6 Dec 31, 2025 | $7.6M6 Dec 31, 2024 | +13.7% |
| Raw materials | $4.9M6 Dec 31, 2025 | $4.0M6 Dec 31, 2024 | +23.0% |
| Work in process | $2.2M6 Dec 31, 2025 | $1.9M6 Dec 31, 2024 | +14.4% |
| Finished goods | $2.7M6 Dec 31, 2025 | $2.7M6 Dec 31, 2024 | +0.9% |
Properties, in its own words
We currently lease approximately 60,000 square foot facility which consists of office, warehousing, manufacturing and research space located at 5115 Ulmerton Road, Clearwater, Florida.
Apyx Bulgaria EOOD leases approximately 27,000 square feet of office, warehousing and manufacturing facilities located in Sofia, Bulgaria.
Item 2 of the 10-K filed Mar 10, 2026.5
Leadership
Who has led Apyx Medical Corp, and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerCharles D. Goodwin Ii. Jan 3, 2018 to now14
- Chief executive officerRobert Gershon Dec 23, 2013 to Sep 27, 201715
- Chief executive officerAndrew Makrides Jan 17, 2006 to Jul 19, 201216
- PresidentJ. Robert Saron Jul 19, 2012 to Sep 27, 201717
- PresidentAndrew Makrides Jan 17, 2006 to Feb 1, 200716
- Chief financial officerMathew C. Hill Dec 6, 2023 to now18
- Chief financial officerTara Semb Jan 11, 2019 to Jan 13, 202319
- Chief financial officerJay D. Ewers Oct 21, 2015 to Jan 11, 201820
- Chief financial officerPeter Donato May 12, 2014 to May 12, 201421
- Chief financial officerGary Pickett Mar 17, 2008 to Jul 19, 201222
- Chief operating officerShawn David Roman Jan 17, 2025 to now23
- Chief operating officerMoshe Citronowicz Jan 4, 2008 to May 13, 200924
Board members and other officers (26)
- Executive Vice PresidentTodd Hornsby Jan 15, 2019 to Jan 11, 202425
- Vice President of OperationsMoshe Citronowicz Jan 6, 2006 to now26
- VP of MarketingJ. Robert Saron Jan 10, 2006 to May 13, 200927
- Board memberStavros G. Vizirgianakis May 9, 2024 to now28
- Board memberWendy Lauren Levine Sep 7, 2021 to now29
- Board memberMinnie Baylor-Henry Aug 15, 2019 to now30
- Board memberCharles D. Goodwin Ii. Jan 3, 2018 to now14
- Board memberScott Richard Davidson Aug 8, 2016 to Aug 8, 201631
- Board memberCharles T. Orsatti May 18, 2015 to Aug 4, 201632
- Board memberJohn C. Andres Sep 11, 2014 to Aug 12, 202433
- Board memberIan Sheffield Dec 23, 2013 to Nov 23, 201534
- Board memberRobert Gershon Dec 23, 2013 to Sep 27, 201715
- Board memberMichael Geraghty Mar 23, 2011 to Aug 12, 202435
- Board memberLawrence Waldman Mar 30, 2011 to now36
- Board memberGregory Alan Konesky Feb 1, 2010 to Dec 29, 201137
- Board memberSteven Maclaren Jul 23, 2010 to Jul 23, 201038
- Board memberPeter Pardoll Nov 18, 2009 to Dec 6, 201039
- Board memberAugust Lentricchia Mar 17, 2008 to Jan 30, 201440
- Board memberMoshe Citronowicz Jan 6, 2006 to Jan 4, 200826
- Board memberJ. Robert Saron Jan 10, 2006 to Sep 27, 201727
- Board memberAndrew Makrides Jan 17, 2006 to Aug 15, 202316
- Board memberGeorge W. Kromer Jan 20, 2006 to Oct 4, 201341
- Board memberBrian Madden Feb 8, 2006 to Nov 10, 200942
- Board memberMichael G. Norman Feb 8, 2006 to Feb 3, 201443
- Board memberAlfred Greco V. Feb 10, 2006 to Feb 10, 200644
- Board memberRandy D. Rossi Feb 10, 2006 to Sep 3, 200845
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Apyx Bulgaria EOOD Bulgaria4
- Apyx China Holding Corp. Delaware4
- Apyx SY Medical Devices (NINGBO) Co., LTD. China4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
Timeline
- Sep 29, 20268-K Other events46
- Aug 7, 20268-K Executive or director change; Shareholder vote47
- Aug 6, 20268-K Results of operations48
- Jul 24, 20268-K Other events49
- Jun 17, 20268-K Entered a material agreement50
- May 21, 20268-K Other events51
- May 14, 20268-K Other events52
- May 11, 20268-K Other events53
- May 7, 20268-K Results of operations54
- Mar 10, 20268-K Results of operations55
- Jan 12, 20268-K Results of operations56
- Dec 12, 20258-K Bylaws or fiscal year changed57
- Jan 3, 2018New chief executive Charles D. Goodwin Ii. becomes CEO14
- Dec 23, 2013New chief executive Robert Gershon becomes CEO15
- Jan 17, 2006New chief executive Andrew Makrides becomes CEO16
Calendar
Coming up
- Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.05) a share, on Nov 6, 2025.58
When it reported results
- Aug 6, 2026Reported quarterly or annual results48
- May 7, 2026Reported quarterly or annual results54
- Mar 10, 2026Reported quarterly or annual results55
- Jan 12, 2026Reported quarterly or annual results56
- Nov 6, 2025Reported quarterly or annual results59
- Aug 7, 2025Reported quarterly or annual results60
- May 8, 2025Reported quarterly or annual results61
- Mar 13, 2025Reported quarterly or annual results62
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
214 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 57 major events, 80 insider forms, 32 large holders, 25 other. The latest 20:
- Sep 29, 20268-K EDGAR
- Aug 7, 20268-K EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 24, 20268-K EDGAR
- Jul 21, 2026SCHEDULE 13G/A EDGAR
- Jul 2, 20264 EDGAR
- Jun 26, 2026DEF 14A EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20268-K EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 1, 2026SD EDGAR
- May 21, 20268-K EDGAR
The 214 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
7 open-market trades by officers, directors and large owners since October 2021: 5 buys and 2 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | HILL MATTHEW CChief Financial Officer | Buy | 6,000 | $1.13 | $6.8K | Form 4 |
| Aug 13, 2024 | HILL MATTHEW CChief Financial Officer | Buy | 5,336 | $1.13 | $6.0K | Form 4 |
| Dec 12, 2023 | HILL MATTHEW CChief Financial Officer | Buy | 2,500 | $2.19 | $5.5K | Form 4 |
| Nov 14, 2023 | Goodwin Charles D. IIChief Executive Officer | Buy | 50,000 | $1.57 | $78.5K | Form 4 |
| Jun 26, 2023 | Hornsby ToddExecutive Vice President | Sale | 15,000 | $7.56 | $113.4K | Form 4 |
| Jun 26, 2023 | Hornsby ToddExecutive Vice President | Sale | 15,000 | $7.56 | $113.4K | Form 4 |
| Aug 29, 2022 | Goodwin Charles D. IIChief Executive Officer | Buy | 11,750 | $5.96 | $70.1K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- ROYCE & ASSOCIATES LPSCHEDULE 13G/A, 5 filings Jan 23, 2024 to Jul 21, 202663
- Nantahala Capital Management, LLCSCHEDULE 13G/A, 2 filings Feb 14, 2025 to Feb 13, 202664
- Archon Capital Management LLCSC 13G, 6 filings Feb 14, 2022 to Oct 31, 202465
- Stavros G. VizirgianakisSC 13D/A, 2 filings Apr 1, 2024 to May 9, 202466
- Orin HirschmanSC 13G/A, 5 filings May 12, 2023 to Mar 25, 202467
- Divisadero Street Capital Management, LPSC 13G/A, 2 filings May 19, 2023 to Feb 14, 202468
- PURA VIDA INVESTMENTS, LLCSC 13G/A, 3 filings Nov 23, 2022 to Feb 14, 202469
- RTW INVESTMENTS, LPSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202470
- Cowen Financial Products LLCSC 13G/A, 3 filings Jan 20, 2022 to Feb 2, 202471
- BlackRockSC 13G, 2 filings Feb 1, 2022 to Jul 8, 202272
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Charles D. Goodwin | 60 | $1.2M73 | |
| 2025 | Mathew Hill | $851.8K73 | ||
| 2025 | Shawn Roman | 55 | $538.6K73 | |
| 2025 | Moshe Citronowicz | 73 | $534.3K73 | |
| 2024 | CEO and Director | $976.0K73 | ||
| 2024 | CFOTreasurer and Secretary | $780.2K73 | ||
| 2024 | Senior VicePresident | $483.5K73 | ||
| 2024 | Chief Operating Officer | $26.6K73 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 68. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Apyx Medical Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARApyx Medical Corp1
- CIK0000719135
- Employer ID (EIN)11-26446115
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address5115 Ulmerton Road, Clearwater, FL 337601
- Phone72738423231
- Shares outstanding42,124,023 as of Aug 5, 202613
- Public float$79.8M as of Jun 30, 20255
- AuditorRSM US LLP, Tampa, Florida PCAOB ID 49; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceDec 21, 19951
- Filings989 in all: 4 (295), 8-K (189), 10-Q (61), SC 13G/A (60), 10QSB (35), 3 (28), 4/A (26), DEF 14A (25)1
All 52 form types
10-K (20), SC 13G (19), 5 (18), 10QSB/A (14), UPLOAD (14), SC 13D (13), SD (13), 10KSB (12), S-8 (12), 10KSB/A (10), S-3/A (10), 10-K/A (9), S-3 (8), 10-Q/A (7), EFFECT (7), NT 10-Q (7), 424B5 (6), 8-K/A (6), CORRESP (6), PRE 14A (6), PRER14A (6), SC 13D/A (6), NT 10-K (4), SB-2/A (4), 144 (3), CT ORDER (3), D (3), DEFA14A (3), SCHEDULE 13G/A (3), 3/A (2), 424B3 (2), 424B7 (2), 25 (1), 424B1 (1), 424B2 (1), 8-A12B (1), 8-A12B/A (1), ARS (1), CERT (1), CERTAMX (1), DEFR14A (1), NTN 10Q (1), S-4/A (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (10-K) Mar 10, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Jun 26, 2026
Latest 8-K (8-K) Sep 29, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.001 Par Value | APYX | Nasdaq |
From the cover page of the 10-K filed Mar 10, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks Apyx Medical Corp names in Item 1A of its 10-K filed Mar 10, 2026: 25 risks under these headings, as written.5
- Risks Relating to Our Business
- Macroeconomic trends including inflation and higher interest rates may adversely affect our financial condition, results of operations and cash flows.
- The health of the economy may affect consumer purchases of discretionary services, such as cosmetic and aesthetic services, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.
- Our revenue could decline due to changes in credit markets and decisions made by credit providers.
- We have had a history of operating losses that have impacted our overall cash flows and may impact our ability to continue as a going concern. We anticipate that we may need to adjust our operating expenditures to be commensurate with our expected levels of revenue and/or raise additional capital to finance operations.
- Our indebtedness levels and achievement of covenants could impact our business.
- The aesthetic equipment market is characterized by rapid innovation. To compete effectively, we must develop and/or acquire new products, seek regulatory clearance, ensure adequate product supply, execute successful marketing, and identify new markets for our technology.
- Even if we are successful in developing new, or enhancing our existing products, there are various circumstances that could prevent their successful commercialization.
- The energy-based medical device industry for the aesthetics market is highly competitive and we may be unable to compete effectively.
- If we are unable to protect our patents or other proprietary rights, or if we infringe on the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged.
- We have been, and may in the future, become subject to litigation proceedings that could materially and adversely affect our business.
- We rely on certain suppliers, subcontractors, and manufacturers for raw materials and other products and are vulnerable to fluctuations in the availability and price of such products and services.
The other 14 risks
- Our manufacturing facilities are located in Clearwater, Florida and Sofia, Bulgaria and could be affected due to multiple weather risks, including risks to our Florida facility from hurricanes and similar phenomena.
- If there is not sufficient consumer demand for the procedures performed with our products, surgeon demand for our products could be inhibited, resulting in unfavorable operating results and reduced growth potential.
- Quality problems and product liability claims could lead to recalls or safety alerts, reputational harm, adverse verdicts or costly settlements, and could have a material adverse effect on our business, results of operations, financial condition and cash flows.
- Risk Related to Government Regulations
- Product Approval and Monitoring
- We are subject to costly and complex laws and governmental regulations and any adverse regulatory action may materially adversely affect our financial condition and business operations.
- Environmental Regulation
- Anti-Corruption Regulation
- We are subject to governmental export controls and regulations that could impair our ability to compete in international markets due to licensing requirements and subject us to potential liability if we are not in compliance with applicable laws. Any non-compliance could have a material adverse effect on our business, financial condition, results of operations and cash flows.
- Risks Relating to Our Stock
- The market price of our stock has been and may continue to be highly volatile.
- We have no present intention to pay dividends on our common stock and, even if we change that policy, we may be unable to pay dividends.
- Issuance of equity through our shelf registration statement, as well as the exercise of options and warrants issued by us will dilute the ownership interest of existing stockholders.
- General Risks
- We may, in the future, identify deficiencies in internal controls over financial reporting.
- We rely on our management team and other key personnel, and we may lose key personnel or fail to attract, train, and retain other talented personnel.
- We are at risk of being the victim of a cyber-attack or a security breach that may expose confidential customer, product and Company data or compromise our internal IT infrastructure. This could lead to liabilities resulting from failure to comply with US and foreign data security and privacy regulations and negative impacts to our business operations.
- Adverse global and regional economic conditions could materially adversely affect the Company’s business, results of operations and financial condition.
- The Company’s business can be impacted by political events, trade and other international disputes, war, terrorism, natural disasters, public health issues, industrial accidents and other business interruptions.
- Changes in U.S. or foreign trade policies could significantly increase the cost of imported goods into the United States, which may materially reduce our sales or profitability.
Legal proceedings
See Note 17 of Notes to Consolidated Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARJ. Robert Saron, President
- 18
- 19SEC EDGARTara Semb, Chief financial officer
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27SEC EDGARJ. Robert Saron, VP of Marketing
- 28
- 29SEC EDGARWendy Lauren Levine, Board member
- 30SEC EDGARMinnie Baylor-Henry, Board member
- 31SEC EDGARScott Richard Davidson, Board member
- 32SEC EDGARCharles T. Orsatti, Board member
- 33SEC EDGARJohn C. Andres, Board member
- 34SEC EDGARIan Sheffield, Board member
- 35SEC EDGARMichael Geraghty, Board member
- 36SEC EDGARLawrence Waldman, Board member
- 37SEC EDGARGregory Alan Konesky, Board member
- 38SEC EDGARSteven Maclaren, Board member
- 39SEC EDGARPeter Pardoll, Board member
- 40SEC EDGARAugust Lentricchia, Board member
- 41SEC EDGARGeorge W. Kromer, Board member
- 42SEC EDGARBrian Madden, Board member
- 43SEC EDGARMichael G. Norman, Board member
- 44SEC EDGARAlfred Greco V., Board member
- 45SEC EDGARRandy D. Rossi, Board member
- 46SEC EDGAROther events
- 47
- 48SEC EDGARResults of operations
- 49SEC EDGAROther events
- 50SEC EDGAREntered a material agreement
- 51SEC EDGAROther events
- 52SEC EDGAROther events
- 53SEC EDGAROther events
- 54SEC EDGARResults of operations
- 55SEC EDGARResults of operations
- 56SEC EDGARResults of operations
- 57SEC EDGARBylaws or fiscal year changed
- 58NasdaqNasdaq calendar
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73